Adding immune checkpoint inhibitors to percutaneous hepatic perfusion may improve survival outcomes in metastatic uveal melanoma.

HealthDay News — For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, ...

Metastatic uveal melanoma commonly spreads to the liver, and percutaneous hepatic perfusion can help control tumors within ...

A groundbreaking study from Tata Memorial Hospital shows that using ultra-low doses of nivolumab, an immunotherapy drug, can effectively treat cancer while drastically reducing costs by 90%. This ...

Adding the dual checkpoint inhibitor regimen of ipilimumab (Yervoy) and nivolumab (Opdivo) to percutaneous hepatic perfusion significantly reduced the risk of disease progression or death in ...

Rosemary Andrew from Oldham has been living with renal cell cancer since 2022 and is now receiving a faster immunotherapy ...

Rosemary Andrew from Oldham has been living with renal cell cancer since 2022 and is now receiving a faster immunotherapy ...

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger ...

Delcath Systems, Inc. , ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

In Perioperative Immunotherapy Advances: Insights from CheckMate-77T and KEYNOTE-671, our panel delves into the following ...

Predictable reimbursement is a primary operational determinant of biosimilar longevity in practices, frequently outweighing ...